Antares Pharma Inc Stock Price, News & Analysis

Antares Pharma reported a 17% revenue increase year-over-year, totaling $40.0 million for Q3 2020, alongside a net income of $5.0 million ($0.03 EPS). Year-to-date revenue reached $105.5 million, a 23% growth compared to 2019.

XYOSTED's prescriptions surged 129% year-over-year, credited to strong demand for at-home testosterone therapy amid the pandemic. The company also secured an exclusive license for NOCDURNA, enhancing its urology portfolio. Full-year revenue guidance remains at $135 million to $155 million, projecting growth of 9% to 25%.

Antares Pharma, Inc. (NASDAQ: ATRS) will announce its Q3 2020 financial results on November 5, 2020, before market opening. A conference call to discuss the results is scheduled for the same day at 8:30 am ET. Dial-in numbers are available for domestic and international callers, with a conference ID of 6925216. A live webcast will also be accessible on Antares Pharma's investor relations website. The company specializes in self-administered injectable pharmaceutical products and has multiple FDA-approved products, including XYOSTED® and OTREXUP®.

Antares Pharma, Inc. (NASDAQ: ATRS) announced that its CEO, Robert F. Apple, will present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference. The presentation is scheduled for September 14, 2020, at 1:30 PM ET, featuring a fireside chat format along with 1x1 meetings. Investors can access a live webcast through the company's website. Antares specializes in self-administered injectable products and has a portfolio including FDA-approved medications such as XYOSTED® and OTREXUP®. The company maintains partnerships with leading pharmaceuticals like Teva and Pfizer.

Antares Pharma, Inc. (NASDAQ: ATRS) has announced the European launch of its multi-dose pen platform for Teriparatide Injection, a generic osteoporosis treatment developed in partnership with Teva. This product is now available in multiple European countries including Austria, Croatia, and the UK, with further launches anticipated. This marks a significant milestone in Antares' collaboration with Teva, following previous successful product launches. Antares is responsible for manufacturing the multi-dose pen used in the product, with global marketing plans in place.

Antares Pharma (NASDAQ: ATRS) has appointed Patrick Shea as Senior Vice President of Commercial, succeeding Edward Kessig who is retiring. Shea, with over 30 years in pharmaceutical sales and marketing, will lead commercial activities for the company, focusing on driving growth for XYOSTED and exploring new product opportunities. CEO Robert F. Apple emphasized Shea's extensive background and the importance of adapting to market challenges, notably a shift to virtual detailing during the COVID-19 pandemic that resulted in a double-digit increase in prescriptions for XYOSTED in Q2 2020.

Antares Pharma, Inc. (NASDAQ: ATRS) announced that CEO Robert F. Apple will present at the Raymond James Human Health Innovation Conference on June 18, 2020, at 9:40 a.m. ET. A live webcast will be accessible on the company's website under the 'For Investors' section. Antares Pharma focuses on developing self-administered injectable pharmaceutical products and has strategic alliances with major companies like Teva and Pfizer. The company’s FDA-approved products include XYOSTED® and OTREXUP®.

Antares Pharma reported first-quarter 2020 revenue of $33.1 million, marking a 42% increase year-over-year. Proprietary product revenue surged 163% to $12.6 million, driven by XYOSTED's popularity. Despite a net loss of $2.4 million (loss per share: $0.01), the company generated $5.6 million in cash from operations. Total cash available rose to $50.3 million. The company suspended its 2020 revenue guidance due to uncertainties related to the COVID-19 pandemic. XYOSTED prescriptions grew 18% sequentially, reflecting solid demand amidst global challenges.